Literature DB >> 19251474

Osteonecrosis of the jaws in patients treated with intravenous bisphosphonates (BRONJ): A concise update.

Jose Bagan1, Crispian Scully, Vicente Sabater, Yolanda Jimenez.   

Abstract

Bisphosphonate-related osteonecrosis of the jaws (BRONJ) is a severe complication seen most frequently in patients on intravenous bisphosphonates treatment for malignant diseases. High potency bisphosphonates are generally implicated and risk factors also include dental extractions. Prevention is of paramount importance. Management is controversial but there is little evidence basis and the consensus is to be conservative. Recent advances in this area are summarised in this concise review.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19251474     DOI: 10.1016/j.oraloncology.2009.01.002

Source DB:  PubMed          Journal:  Oral Oncol        ISSN: 1368-8375            Impact factor:   5.337


  23 in total

1.  Bevacizumab-associated osteonecrosis of the wrist and knee in three pediatric patients with recurrent CNS tumors.

Authors:  Jason Fangusaro; Sridharan Gururangan; Regina I Jakacki; Sue C Kaste; Stewart Goldman; Ian F Pollack; James M Boyett; Larry E Kun
Journal:  J Clin Oncol       Date:  2012-11-19       Impact factor: 44.544

2.  Interrelationship of clinical, radiographic and haematological features in patients under bisphosphonate therapy.

Authors:  Valesca S Koth; Maria A Figueiredo; Fernanda G Salum; Karen Cherubini
Journal:  Dentomaxillofac Radiol       Date:  2017-02-17       Impact factor: 2.419

Review 3.  Interventions for managing medication-related osteonecrosis of the jaw.

Authors:  Natalie H Beth-Tasdogan; Benjamin Mayer; Heba Hussein; Oliver Zolk; Jens-Uwe Peter
Journal:  Cochrane Database Syst Rev       Date:  2022-07-12

4.  Osteo-radio-necrosis (ORN) and bisphosphonate-related osteonecrosis of the jaws (BRONJ): the histopathological differences under the clinical similarities.

Authors:  Konstantinos T Mitsimponas; Patrick Moebius; Kerstin Amann; Philipp Stockmann; Karl-Andreas Schlegel; Friedrich-Wilhelm Neukam; Falk Wehrhan
Journal:  Int J Clin Exp Pathol       Date:  2014-01-15

5.  Technetium-99 conjugated with methylene diphosphonate ameliorates ovariectomy-induced osteoporotic phenotype without causing osteonecrosis in the jaw.

Authors:  Yinghua Zhao; Lei Wang; Yi Liu; Kentaro Akiyama; Chider Chen; Ikiru Atsuta; Tao Zhou; Xiaohong Duan; Yan Jin; Songtao Shi
Journal:  Calcif Tissue Int       Date:  2012-10-12       Impact factor: 4.333

6.  IL-17-mediated M1/M2 macrophage alteration contributes to pathogenesis of bisphosphonate-related osteonecrosis of the jaws.

Authors:  Qunzhou Zhang; Ikiru Atsuta; Shiyu Liu; Chider Chen; Shihong Shi; Songtao Shi; Anh D Le
Journal:  Clin Cancer Res       Date:  2013-04-24       Impact factor: 12.531

7.  Bisphosphonates and osteonecrosis: an open matter.

Authors:  Paolo Vescovi
Journal:  Clin Cases Miner Bone Metab       Date:  2012-12-20

8.  Surgical Approach and Laser Applications in BRONJ Osteoporotic and Cancer Patients.

Authors:  Paolo Vescovi; Elisabetta Merigo; Marco Meleti; Maddalena Manfredi; Carlo Fornaini; Samir Nammour
Journal:  J Osteoporos       Date:  2012-05-08

9.  Cell-based immunotherapy with mesenchymal stem cells cures bisphosphonate-related osteonecrosis of the jaw-like disease in mice.

Authors:  Takashi Kikuiri; Insoo Kim; Takyoshi Yamaza; Kentaro Akiyama; Qunzhou Zhang; Yunsheng Li; Chider Chen; WanJun Chen; Songlin Wang; Anh D Le; Songtao Shi
Journal:  J Bone Miner Res       Date:  2010-07       Impact factor: 6.741

Review 10.  Interventions for managing medication-related osteonecrosis of the jaw.

Authors:  Natalie H Beth-Tasdogan; Benjamin Mayer; Heba Hussein; Oliver Zolk
Journal:  Cochrane Database Syst Rev       Date:  2017-10-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.